Pacific Biosciences of Californ

PACB

Healthcare

$1.61+1.58%vs prev close

$0.85

$2.73

52W Range

+0.27 (+18.75%)Past 1M

Price

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

25,022,893

Portfolio Weight

0.3%

in ETF 1.35%

Est. Value

$39M

30D Net

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Hold

Strong Sell

Analyst Targets

avg.

$2.38

vs Current ▲ +48.0% upside

Current$1.61

Low ~ High$1.00 ~ $3.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Barclays

Underweight

$1.00

-37.69%

$1.57

Maintain

2026-04-14

Barclays

Underweight

$1.50

-6.54%

$1.38

Downgrade

2026-03-06

Barclays

Equal-Weight

$2.00

+24.61%

$2.12

Maintain

2025-12-15

Piper Sandler

Neutral

$2.00

+24.61%

$1.86

Maintain

2025-11-11

Stephens & Co.

Overweight

$2.00

+24.61%

$1.76

Maintain

2025-11-10

1 / 1

Avg Target

$2.38

vs Current ▲ +48.0% upside

Buy

8 analysts

Buy 4Hold 3Strong Sell 1

Low $1.00

Current $1.61

High $3.00

Firm	Position	Target	Upside	Close	Action	Date
Barclays	Underweight	$1.00	-37.69%	$1.57	Maintain	26.04.14
Barclays	Underweight	$1.50	-6.54%	$1.38	Downgrade	26.03.06
Barclays	Equal-Weight	$2.00	+24.61%	$2.12	Maintain	25.12.15
Piper Sandler	Neutral	$2.00	+24.61%	$1.86	Maintain	25.11.11
Stephens & Co.	Overweight	$2.00	+24.61%	$1.76	Maintain	25.11.10

1 / 1

Price Information

Previous Close$1.58

Open$1.58

Day Range$1.58 - $1.61

52-Week Range$0.85 - $2.73

1-Year Change39.82%

Trading Volume

Volume785,016

Avg Volume (3mo)6,003,286

Valuation

Market Cap498.3M

Book Value$0.02

Shares Outstanding310,487,099

Financials

Revenue (TTM)160.0M

Net Income-546,376,000

EPS$-1.82

EBITDA-169,226,000

Profitability

P/E Ratio-

P/B Ratio89.17

Return on Equity (ROE)-213.45%

Return on Assets (ROA)-33.73%

Profit Margin0.00%

EV/EBITDA-5.32

Beta2.40

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)48.15

Company Overview

Pacific Biosciences of California (PACB) designs, develops, and manufactures advanced sequencing solutions, primarily their SMRT technology and instruments like Revio and Sequel, to address complex genetic challenges. They offer a comprehensive suite of systems, consumables, and reagent kits for various applications. PACB serves a broad range of research and clinical institutions, including pharmaceutical, agricultural, and public health organizations, positioning itself as a key player in the genomics field.

P/B

89.17

High valuation

ROE

-213.5%

Persistent loss

Beta

2.40

Extreme volatility

RSI(14)

48.1

Neutral

AI-generated summary. Not investment advice.